Advanced search
Publication Cover
Biomarkers in Medicine Volume 1, 2007 - Issue 4
Submit an article Journal homepage
478
Views
1
CrossRef citations to date
0
Altmetric
Review

CA125 in Ovarian Cancer

Nathalie Scholler1 Center for Research on Early Detection & Cure of Ovarian Cancer School of Medicine,University of Pennsylvania Biomedical Research Building (BRB) II/III,Suite 1355 421 Curie Blvd,PA19104-6080,USA.
&
Nicole Urban2 Fred Hutchinson Cancer Research Center,Molecular Diagnostics Program,Division of Public Health Science,1100 Fairview avenue N, MailStop M2 B230 Seattle,WA98109,USA.Correspondence[email protected]
[email protected]
Pages 513-523 | Published online: 17 Dec 2007

Bibliography

  • Bast RC Jr , FeeneyM, LazarusH,NadlerLM, ColvinRB, KnappRC: Reactivity of a monoclonal antibody with human ovarian carcinoma.J. Clin. Invest.68, 1331–1337 (1981).
  • Papsidero LD , WangMC, ValenzuelaLA, MurphyGP, ChuTM: A prostate antigen in sera of prostatic cancer patients.Cancer Res.40, 2428–2432 (1980).
  • Rao AR , MotiwalaHG, KarimOM: The discovery of prostate-specific antigen.BJU Int. (2007) (Epub ahead of print).
  • Feeley KM , WellsM: Precursor lesions of ovarian epithelial malignancy.Histopathology38, 87–95 (2001).
  • Bischof P , TsengL, BrioschiPA, HerrmannWL: Cancer antigen 125 is produced by human endometrial stromal cells.Hum. Reprod.1, 423–426 (1986).
  • Kenemans P , YedemaCA, BonGG, von Mensdorff-PouillyS: CA 125 in gynecological pathology – a review.Eur. J. Obstet. Gynecol. Reprod. Biol.49, 115–124 (1993).
  • Tamakoshi K , KikkawaF, HasegawaNet al.: Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.Gynecol. Obstet. Invest.39, 125–129 (1995).
  • Dorum A , KristensenGB, AbelerVM, TropeCG, MollerP: Early detection of familial ovarian cancer.Eur. J. Cancer32A, 1645–1651 (1996).
  • Eagle K , LedermannJA: Tumor markers in ovarian malignancies.Oncologist2, 324–329 (1997).
  • Fures R , BukovicD, HodekB, KlaricB, HermanR, GrubisicG: Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.Coll. Antropol.23, 189–194 (1999).
  • Jacobs IJ , MenonU: Progress and challenges in screening for early detection of ovarian cancer.Mol. Cell Proteomics3, 355–366 (2004).
  • Berruti A , TampelliniM, TortaM, BunivaT, GorzegnoG, DogliottiL: Prognostic value in predicting overall survival of two mucinous markers: CA 15–3 and CA 125 in breast cancer patients at first relapse of disease.Eur. J. Cancer30A, 2082–2084 (1994).
  • Norum LF , EriksteinB, NustadK: Elevated CA125 in breast cancer – a sign of advanced disease.Tumour Biol.22, 223–228 (2001).
  • Hedman M , ArnbergH, WernlundJ, RiskaH, BrodinO: Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma.AntiCancer Res.23, 531–536 (2003).
  • Bairey O , BlicksteinD, StarkPet al.: Serum CA 125 as a prognostic factor in non-Hodgkin‘s lymphoma.Leuk. Lymphoma44, 1733–1738 (2003).
  • Burney IA , SiddiquiT, SiddiquiI: Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin‘s lymphoma: correlation with tumor parameters and disease activity.Cancer85, 755–756 (1999).
  • Kutluk T , VaranA, ErbasB, BuyukpamukcuM: Serum CA 125 levels in children with non-Hodgkin‘s lymphoma.Pediatr. Hematol. Oncol.16, 311–319 (1999).
  • Zidan J , HusseinO, BasherW, ZoharS: Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin‘s lymphoma.Oncologist9, 417–421 (2004).
  • Camera A , VillaMR, RoccoSet al.: Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement.Cancer88, 75–78 (2000).
  • Yamamoto M , BabaH, TohY, OkamuraT, MaeharaY: Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients.J. Cancer Res. Clin. Oncol. (2007) (In press).
  • Whiteley MS , MarshallJ: Raised serum CA125 level in leiomyoma and leiomyosarcoma of gastrointestinal origin.Br. J. Surg.80, 1551 (1993).
  • Meden H , Fattahi-MeibodiA: CA 125 in benign gynecological conditions.Int. J. Biol. Markers13, 231–237 (1998).
  • Ismail MA , RotmenschJ, MercerLJ, BlockBS, SaltiGI, HoltJA: CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders.J. Reprod. Med.39, 510–512 (1994).
  • Cheng YM , WangST, ChouCY: Serum CA-125 in preoperative patients at high risk for endometriosis.Obstet. Gynecol.99, 375–380 (2002).
  • Kitawaki J , IshiharaH, KoshibaHet al.: Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas.Hum. Reprod.20, 1999–2003 (2005).
  • Abrao MS , PodgaecS, PinottiJA, de OliveiraRM: Tumor markers in endometriosis.Int. J. Gynaecol. Obstet.66, 19–22 (1999).
  • Baalbergen A , JanssenJW, vanderWeidenRM: CA-125 levels are related to the likelihood of pregnancy after in vitro fertilization and embryo transfer.Am. J. Reprod. Immunol.43, 21–24 (2000).
  • Miller KA , DeatonJL, PittawayDE: Evaluation of serum CA 125 concentrations as predictors of pregnancy with human in vitro fertilization.Fertil. Steril.65, 1184–1189 (1996).
  • Mazor M , BashiriA, GhezziFet al.: Maternal serum CA 125 is of prognostic value in patients with uterine bleeding in the detection of small-for-gestational-age neonates.Eur. J. Obstet. Gynecol. Reprod. Biol.67, 143–147 (1996).
  • Spitzer M , KaushalN, BenjaminF: Maternal CA-125 levels in pregnancy and the puerperium.J. Reprod. Med.43, 387–392 (1998).
  • Bon GG , KenemansP, DekkerJJet al.: Fluctuations in CA 125 and CA 15–3 serum concentrations during spontaneous ovulatory cycles.Hum. Reprod.14, 566–570 (1999).
  • Crespo Valades E , Malmierca CorralM: Elevated CA125 in chronic liver disease with ascites.Gastroenterol. Hepatol.27, 558 (2004).
  • Kalambokis G , KostoulaA, EconomouM, TsianosEV: Tumor necrosis factor-α-related intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites.Clin. Chem.51, 2207–2208 (2005).
  • Kouris NT , ZacharosID, KontogianniDDet al.: The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters.Eur. J. Heart Fail.7, 199–203 (2005).
  • Kumar KS , LeeWM: Chylous ascites with marked elevation of CA-125 in cirrhosis.Am. J. Gastroenterol.95, 3313–3314 (2000).
  • Schoniger-Hekele M , MullerC: The combined elevation of tumor markers CA 19–9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.Dig. Dis. Sci.51, 338–345 (2006).
  • Xiao WB , LiuYL: Elevation of serum and ascites cancer antigen 125 levels in patients with liver cirrhosis.J. Gastroenterol. Hepatol.18, 1315–1316 (2003).
  • Bilgin T , KarabayA, DolarE, DeveliogluOH: Peritoneal tuberculosis with pelvic abdominal mass, ascites and elevated CA 125 mimicking advanced ovarian carcinoma: a series of 10 cases.Int. J. Gynecol. Cancer11, 290–294 (2001).
  • Fernandez J , De QuirosB, TelentiMet al.: CA125 Serum levels in tubercolosis patients.Int. J. Biol. Markers10, 180–181 (1995).
  • Kilic G , BlanksteinJ, KadanoffR: Vertebral tuberculosis presenting with elevated CA-125 and weight loss mimicking ovarian malignancy; case report.Eur. J. Gynaecol. Oncol.24, 561–562 (2003).
  • Koc S , BeydilliG, TulunayGet al.: Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases.Gynecol. Oncol.103, 565–569 (2006).
  • Bast RC Jr , KlugTL, St JohnEet al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N. Engl. J. Med.309, 883–887 (1983).
  • Klug TL , BastRCJr, NiloffJM, KnappRC, ZurawskiVRJr: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas.Cancer Res.44, 1048–1153 (1984).
  • Hovig E , RyePD, WarrenDJ, NustadK: CA 125: the end of the beginning.Tumour Biol.22, 345–347 (2001).
  • Kui Wong N , EastonRL, PanicoMet al.: Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.J. Biol. Chem.278, 28619–28634 (2003).
  • Maeda T , InoueM, KoshibaSet al.: Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16).J. Biol. Chem.279, 13174–13182 (2004).
  • Yin BW , DnistrianA, LloydKO: Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.Int. J. Cancer98, 737–740 (2002).
  • Yin BW , LloydKO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.J. Biol. Chem.276, 27371–27375 (2001).
  • O‘Brien TJ , BeardJB, UnderwoodLJ, DennisRA, SantinAD, YorkL: The CA 125 gene: an extracellular superstructure dominated by repeat sequences.Tumour Biol.22, 348–366 (2001).
  • Nouwen EJ , DauweS, De BroeME: Occurrence of the mucinous differentiation antigen CA125 in genital tract and conductive airway epithelia of diverse mammalian species (rabbit, dog, monkey).Differentiation45, 192–198 (1990).
  • McDonnel AC , Van KirkEA, AustinKJ, HansenTR, BeldenEL, MurdochWJ: Expression of CA-125 by progestational bovine endometrium: prospective regulation and function.Reproduction126, 615–620 (2003).
  • Duraisamy S , RamasamyS, KharbandaS, KufeD: Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16.Gene373, 28–34 (2006).
  • Jackson E , AndersonK, AshwellC, PetitteJ, MozdziakPE: CA125 expression in spontaneous ovarian adenocarcinomas from laying hens.Gynecol. Oncol.104, 192–198 (2007).
  • Lloyd KO , YinBW, KudryashovV: Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule.Int. J. Cancer71, 842–850 (1997).
  • Lloyd KO , YinBW: Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3.Tumour Biol.22, 77–82 (2001).
  • O‘Brien TJ , TanimotoH, KonishiI, GeeM: More than 15 years of CA 125: what is known about the antigen, its structure and its function.Int. J. Biol. Markers13, 188–195 (1998).
  • Jankovic MM , TapuskovicBS: Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen.Hum. Reprod.20, 2632–2638 (2005).
  • Nustad K , LebedinY, LloydKOet al.: Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop.Tumour Biol.23, 303–314 (2002).
  • Bork P , PatthyL: The SEA module: a new extracellular domain associated with O-glycosylation.Protein Sci.4, 1421–1425 (1995).
  • Murdoch WJ , Van KirkEA, SmedtsAM: Complement-inhibiting effect of ovarian cancer antigen CA-125.Cancer Lett. (2005).
  • el Ouagari K , TeissieJ, BenoistH: Glycophorin A protects K562 cells from natural killer cell attack. Role of oligosaccharides.J. Biol. Chem.270, 26970–26975 (1995).
  • Yoshimura M , IharaY, OhnishiAet al.: Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization.Cancer Res.56, 412–418 (1996).
  • Patankar MS , JingY, MorrisonJCet al.: Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.Gynecol. Oncol.99, 704–713 (2005).
  • Belisle JA , GubbelsJA, RaphaelCAet al.: Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).Immunology122(3), 418–429 (2007).
  • Barondes SH , CooperDN, GittMA, LefflerH: Galectins. Structure and function of a large family of animal lectins.J. Biol. Chem.269, 20807–20810 (1994).
  • Perillo NL , PaceKE, SeilhamerJJ, BaumLG: Apoptosis of T cells mediated by galectin-1.Nature378, 736–739 (1995).
  • Terness P , KallikourdisM, BetzAG, RabinovichGA, SaitoS, ClarkDA: Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells.Am. J. Reprod. Immunol.58, 238–254 (2007).
  • Seelenmeyer C , WegehingelS, LechnerJ, NickelW: The cancer antigen CA125 represents a novel counter receptor for galectin-1.J. Cell Sci.116, 1305–1318 (2003).
  • Zhang JQ , NicollG, JonesC, CrockerPR: Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes.J. Biol. Chem.275, 22121–22126 (2000).
  • Talbi S , HamiltonAE, VoKCet al.: Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women.Endocrinology147, 1097–1121 (2006).
  • Saito S , ShiozakiA, SasakiY, NakashimaA, ShimaT, ItoM: Regulatory T cells and regulatory natural killer (NK) cells play important roles in feto-maternal tolerance.Semin. Immunopathol.29, 115–122 (2007).
  • Scholler N , FuN, YangYet al.: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.Proc. Natl Acad. Sci. USA96, 11531–11536 (1999).
  • Robinson BW , CreaneyJ, LakeRet al.: Soluble mesothelin-related protein-a blood test for mesothelioma.Lung Cancer49(Suppl. 1), S109–S111 (2005).
  • Hassan R , LaszikZG, LernerM, RaffeldM, PostierR, BrackettD: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.Am. J. Clin. Pathol.124, 838–845 (2005).
  • Chang K , PastanI: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proc. Natl Acad. Sci. USA93, 136–140 (1996).
  • Iacobuzio-Donahue CA , AshfaqR, MaitraAet al.: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.Cancer Res.63, 8614–8622 (2003).
  • Galloway ML , MurrayD, MoffatDF: The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.Histopathology48, 767–769 (2006).
  • Rump A , MorikawaY, TanakaMet al.: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.J. Biol. Chem.279, 9190–9198 (2004).
  • Gubbels JA , BelisleJ, OndaMet al.: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.Mol. Cancer5(1), 50 (2006).
  • Scholler N , GarvikB, Hayden-LedbetterM, KlineT, UrbanN: Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.Cancer Lett.247, 130–136 (2007).
  • Jemal A , SiegelR, WardEet al.: Cancer statistics, 2006.CA Cancer J. Clin.56, 106–130 (2006).
  • Crum CP , DrapkinR, MironAet al.: The distal fallopian tube: a new model for pelvic serous carcinogenesis.Curr. Opin. Obstet. Gynecol.19, 3–9 (2007).
  • Kindelberger DW , LeeY, MironAet al.: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship.Am. J. Surg. Pathol.31, 161–169 (2007).
  • Lee Y , MironA, DrapkinRet al.: A candidate precursor to serous carcinoma that originates in the distal fallopian tube.J. Pathol.211, 26–35 (2007).
  • Medeiros F , MutoMG, LeeYet al.: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.Am. J. Surg. Pathol.30, 230–236 (2006).
  • Sakahara H , KousakaT, HattoriNet al.: Dissociation in serum CA125 concentrations measured by different monoclonal antibodies.Gynecol. Oncol.52, 301–305 (1994).
  • Kenemans P , VerstraetenAA, van KampGJ, von Mensdorff-PouillyS: The second generation CA 125 assays.Ann. Med.27, 107–113 (1995).
  • Scholler N , CrawfordM, SatoAet al.: Bead-based ELISA assays for validation of ovarian cancer early detection markers.Clin. Cancer Res.12, 2117–2124 (2006).
  • Nap M , VitaliA, NustadKet al.: Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop.Tumour Biol.17, 325–331 (1996).
  • Nustad K , BastRCJr, BrienTJet al.: Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine.Tumour Biol.17, 196–219 (1996).
  • Nustad K , OnsrudM, JanssonB, WarrenD: CA 125-epitopes and molecular size.Int. J. Biol. Markers13, 196–199 (1998).
  • Nagata A , HirotaN, SakaiT, FujimotoM, KomodaT: Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen.Tumour Biol.12, 279–286 (1991).
  • Urban N , DrescherC, EtzioniR, ColbyC: Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening.Control. Clin. Trials18, 251–270 (1997).
  • Genetic/familial high risk assessment: breast and ovarian. In: Clinical Practice Guidelines in Oncology (Volume 1).National Comprehensive Cancer Network (2007).
  • van Haaften-Day C , ShenY, XuFet al.: OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.Cancer92, 2837–2844 (2001).
  • Olivier RI , Lubsen-BrandsmaMA, VerhoefS, van BeurdenM: CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.Gynecol. Oncol.100, 20–26 (2006).
  • Horiuchi A , ItohK, ShimizuMet al.: Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.Gynecol. Oncol.88, 309–317 (2003).
  • Fishman DA , CohenL, BlankSVet al.: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.Am. J. Obstet. Gynecol.192, 1214–21; discussion 1221–1222 (2005).
  • Hogg R , FriedlanderM: Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.J. Clin. Oncol.22, 1315–1327 (2004).
  • Stirling D , EvansDG, PichertGet al.: Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.J. Clin. Oncol.23, 5588–5596 (2005).
  • Skates SJ , MenonU, MacDonaldNet al.: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.J. Clin. Oncol.21, S206–S210 (2003).
  • Skates SJ , HorickN, YuYet al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–3, CA 72–4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.J. Clin. Oncol.22, 4059–4066 (2004).
  • Hellström I , RaycraftJ, Hayden-LedbetterMet al.: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.Cancer Res.63, 3695–3700 (2003).
  • Diamandis EP , BorgonoCA, ScorilasA, HarbeckN, DornJ, SchmittM: Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.Clin. Biochem.37, 823–829 (2004).
  • Salceda S , TangT, KmetMet al.: The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.Exp. Cell Res.306, 128–141 (2005).
  • Bast RC Jr , BadgwellD, LuZet al.: New tumor markers: CA125 and beyond.Int. J. Gynecol. Cancer15(Suppl. 3), 274–281 (2005).
  • Menon U , SkatesSJ, LewisSet al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.J. Clin. Oncol.23, 7919–7926 (2005).
  • McIntosh MW , UrbanN: A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker.Biostatistics4, 27–40 (2003).
  • McIntosh MW , UrbanN, KarlanB: Generating longitudinal screening algorithms using novel biomarkers for disease.Cancer Epidemiol. Biomarkers Prev.11, 159–166 (2002).
  • Zurawski VR Jr , OrjaseterH, AndersenA, JellumE: Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer.Int. J. Cancer42, 677–680 (1988).
  • Bjorge T , LieAK, HovigEet al.: BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study.Br. J. Cancer91, 1829–1834 (2004).
  • Jacobs IJ , SkatesSJ, MacDonaldNet al.: Screening for ovarian cancer: a pilot randomized controlled trial.Lancet353, 1207–1210 (1999).
  • Hermsen BB , von Mensdorff-PouillyS, BerkhofJet al.: Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.J. Clin. Oncol.25, 1383–1389 (2007).
  • Berek JS : Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.Expert Opin. Biol. Ther.4, 1159–1165 (2004).
  • Noujaim AA , SchultesBC, BaumRP, MadiyalakanR: Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 – evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.Cancer Biother. Radiopharm.16, 187–203 (2001).
  • Schultes BC , BaumRP, NiesenA, NoujaimAA, MadiyalakanR: Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).Cancer Immunol. Immunother.46, 201–212 (1998).
  • Baum RP , NoujaimAA, NanciAet al.: Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13.Hybridoma12, 583–589 (1993).
  • Baum RP , NiesenA, HertelAet al.: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.Cancer73, 1121–1125 (1994).
  • Wagner U , KohlerS, ReinartzSet al.: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment.Clin. Cancer Res.7, 1154–1162 (2001).
  • Gordon AN , SchultesBC, GallionHet al.: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.Gynecol. Oncol.94, 340–351 (2004).
  • Berek JS , SchultesBC, NicodemusCF: Biologic and immunologic therapies for ovarian cancer.J. Clin. Oncol.21, S168–S174 (2003).
  • Berek JS , TaylorPT, GordonAet al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.J. Clin. Oncol.22, 3507–3516 (2004).
  • Wagner U , SchlebuschH, KohlerS, SchmollingJ, GrunnU, KrebsD: Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.Hybridoma16, 33–40 (1997).
  • Reinartz S , KohlerS, SchlebuschHet al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II).Clin. Cancer Res.10, 1580–1587 (2004).
  • Sabbatini P , DupontJ, AghajanianCet al.: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Clin. Cancer Res.12, 5503–5510 (2006).
  • Reinartz S , HombachA, KohlerSet al.: Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.Cancer Res.63, 3234–3240 (2003).
  • Chen Y , ClarkS, WongTet al.: Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.Cancer Res.67, 4924–4932 (2007).
  • Singleton J , GuillenDE, ScullyMSet al.: Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen.Tumour Biol.27, 122–132 (2006).
  • Kim R , EmiM, TanabeK, ArihiroK: Tumor-driven evolution of immunosuppressive networks during malignant progression.Cancer Res.66, 5527–5536 (2006).
  • Kusmartsev S , GabrilovichDI: Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer.Cancer Metastasis Rev.25, 323–331 (2006).
  • Bergan L , GrossJA, NevinB, UrbanN, SchollerN: Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/mesothelin-dependent cell attachment.255(2), 263–274Cancer Lett. (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.